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1. Introduction 
Cannabis sativa (Fig. 1.) has been valued for its medicinal as well as its psychotropic properties 
dating back to ancient times. In nineteenth century W.B. O’Shaughnessy used marijuana for 
pain relief and Jean-Jacques Moreau de Tours – French psychiatrist, said, that cannabis is very 
helpful in therapy of psychiatric disorders (Booth, 2004). Main constituents of Cannabis sativa 
were discovered in 1960’s and named after the plant – cannabinoids. The identification of the 
chemical structure of cannabis components and the possibility of obtaining its pure constituents 
were related to a significant increase in scientific interest in this plant. This interest was 
renewed in the 1990's with the description of cannabinoid receptors and the identification of 
an endogenous cannabinoid system in the brain (Zuardi, 2006).  
The most notable of the cannabinoids are: tetrahydrocannabinol (THC) – the most 
psychoactive substance found in the cannabis plant and cannabidiol – constituent which has 
displayed sedative effects. Both constituents can be found in the brown resin secreted by the 
hair which covers female plants (Truta et al., 2002). Cannabinoids bind to the cannabinoid 
receptors (CB receptors), change metabolism of the cells, moderate neurotransmission and 
hormones extraction, what affect main functions of the human body (Demuth et al., 2006, 
ElSohly et al., 2005). 
The cannabinoid receptor family currently includes two types: CB1, characterized mostly in 
neuronal cells and brain, and CB2, characterized in immune cells (lymphocytes and 
macrophages) and tissues (spleen and tonsils) (Demuth et al., 2006). Both receptors are 
proteins and consist of seven transmembrane−spanning domains (Fig. 2.)(Joy et al., 1999). 
The CB1 molecule is larger than CB2. However, both receptor molecules are alike in four of 
the seven regions embedded in the cell membrane (known as the transmembrane regions). 
The intracellular loops of the two receptor subtypes are quite different, which might affect 
the cellular response to the ligand (Szulakowska&Milnerowicz, 2007). Human body also 
produces substances that activate CB receptors, they are known as endocannabinoids. The 
studies have revealed a broad role of endocannabinoids and cannabinoid receptors in a 
variety of physiological processes as neuromodulation, pain and appetite sensation, motor 
learning (Saito et al., 2010).  
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Fig. 1. Cannabis sativa (Kohler, 1887). 
2. Cannabinoids and the immune system  
The study of marijuana cannabinoid biology has led to many important discoveries in 
immunology; not only existence of a new physiological system - the endocannabinoid 
system, but also its role in the regulation of the immune system. Studies examining the 
effect of cannabinoids on immunity have shown that many cellular and cytokine 
mechanisms are suppressed by these agents (Klein&Cabral, 2006). 
2.1 Cellular effects 
Scientists have already suggested in 1970s that cannabinoids can change the number and 
function of T cells. Various functions from cytotoxic T cell killing to antibody production by 
B cells have been examined. Nong and Co. have studied the T-cell rosetting capacity 
of lymphocytes in CD4 and CD8 subsets – it was impaired in peripheral blood cells from 
marijuana users. Scientists examined also the effects on the number of lymphocytes in CD4 
and CD8 subsets. The percentage of CD4 T cells was increased in peripheral blood cells from 
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marijuana smokers, with a mean CD4/CD8 ratio of 1.95 as opposed to 1.27 in controls 
(Nong et al., 2002; Massi et al., 2006). Finally, Klein and Co. proved that cannabinoids affect 
cytotoxic T lymphocytes (CTL) – after incubation with THC, the cytolytic activity of CTL 
was depressed by about 60% (Klein et al., 1991). It also appeared that cannabinoids can 
disrupt proliferation and cytolytic activity in natural killer cells (NK), which plays very 
important role in host defences against tumors and microbes (Massi et al., 2006).  
 
 
Fig. 2. Cannabinoid receptors CB1 and CB2 (Joy et al., 1999). 
Functions of macrophages are also impaired by cannabinoids through either a receptor- or 
non-receptor-mediated mechanism. Studies with pulmonary alveolar macrophages showed 
that cannabinoids significantly lowered the level of tumor necrosis factor ǂ ( TNFǂ) in the 
bronchoalveolar lavage (Klein et al., 1991). Scientists proved that cannabinoids influenced 
the ability of macrophages to process antigens necessary for the activation of CD4+ T 
lymphocytes (McCoy et al., 1999), reduced chemotaxis (Sacerdote et al., 2000) and affect the 
production of arachidonic acid metabolites in macrophage cultures (Berdyshev et al., 2000). 
The influence of cannabinoids on NO production is still unclear (Massi et al., 2006).  
2.2 Cytokines and hormones 
Cannabinoids can modulate the action of cytokines mostly by affecting immune cells, for 
example macrophages or Th cells,  their immunomodulatory properties are complex, what 
was shown in the Table 1.  
Scientists proved that cannabinoids can modulate immune response also by affecting 
hormones release. For example administration of THC, may increase level of 
adrenocorticotropic hormone and corticosterone, what is causing downstream release of 
immunoregulatory molecules as cortizol and sex hormones and inhibition of immune 
response (Massi et al., 2006; Tanasescu&Constantinescu, 2010; Baker et al., 2007). 
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Cannabinoid infulence General result References 
IFNǄ Decreased level Anti-inflammatory action (Zheng et al., 
1992, 1996) 
TNFǂ Decreased level Anti-inflammatory action (Zheng et al., 
1992, 1996) 
Il-1 Decreased level Anti-inflammatory action 
(Kozela et al., 
2010) 
Il-2 Decreased level Anti-inflammatory action 
(Zhu et al., 
1993) 
Il-4 Increased level Action unclear 
(Klein et al., 
2000) 
Il-6 Decreased level Anti-inflammatory action 
(Kozela et al., 
2010) 







Anti-inflammatory action  
(THC)/ Anti-inflammatory 
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Table 1. Cannabinoid influence on cytokines profile 
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Fig. 3. Immune regulation by cannabinoids. Exogenously administered cannabinoids (a, b) 
or endocannabinoids (c) may inhibit the action of the immune response in either the 
periphery (a, b) or the central nervous system (CNS; c) via either a direct (a, c) or indirect (b) 
action on leukocytes (from Baker et al., 2007). 
Cannabinoids can modulate immune reactions in the periphery but also in the brain, 
influence T cell subset balance and cytokine expression. Generally, they alter many 
functions of the immune response, what was shown in the Fig. 3. (Baker et al., 2007). 
3. Immunological consequences of cannabinoids use by HIV/AIDS patients 
Anti-inflammatory potential action of cannabinoids tends to be evident from the studies 
discussed in the previous paragraph. Cannabinoids do induce apoptosis in immune cells 
and alleviate inflammatory responses (Rieder et al., 2010). Even though the progressive 
failure of the immune system is a cause of AIDS disease, no conclusive data have been 
obtained as to potential risk associated with HIV infection and the use of cannabinoids. In 
2003 Abrams and co. examined short-term effects of cannabinoids in patients with HIV-1 
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infection. Scientists measured HIV RNA level and CD4+ and CD8+ cell subsets, during 21 
days of oral and smoked marijuana administration among 67 patients with HIV-1 infection. 
At days 0 and 21, HIV RNA was undetectable in 50% to 55% of patients in each group, the 
mean changes were decreases in both cannabinoid groups: marijuana group and dronabinol 
group. The unadjusted mean increases in CD4+ cell counts were greater for patients 
receiving cannabinoids than for patients receiving placebo. CD8+ cell counts were on 
average 20% greater for patients receiving marijuana than for patients receiving placebo and 
marginally greater (average 10%) for patients receiving dronabinol than for those receiving 
placebo. Authors concluded that smoked and oral cannabinoids did not seem to be unsafe in 
patients with HIV infection with respect to HIV RNA levels, CD4+ and CD8+ cell counts 
(Abrams et al., 2003).  
Kosel and co. decided to examine effects of cannabinoids on the pharmacokinetics of 
indinavir and nelfinavir – protease inhibitors used as a component of highly active 
antiretroviral therapy to treat HIV infection and AIDS. Patients on stable regimens 
containing indinavir or nelfinavir were randomized to one of three treatments: 3.95% THC 
marijuana cigarettes, dronabinol 2.5 mg capsules or placebo capsules administered three 
times daily. The treatment lasted 14 days. Authors concluded that their results after 
marijuana treatment (statistically significant decrease in maximum concentration of 
nelfinavir - C(max)) by -17.4% (P=0.46) and the magnitude of changes in indinavir 
concentration - C(max) by -14.1% (P=0.039)), are likely to have no short-term clinical 
consequence. The use of cannabinoids is unlikely to impact antiretroviral efficacy (Kosel et 
al., 2002).  
4. Therapeutic use of marijuana for people living with HIV/AIDS 
Over 40 million people are affected by HIV/AIDS in the world. There is still no cure 
available for this disease, although remarkable improvements in the quality and life 
expectancy have been achieved. Most of the patients are on long-term treatment with 
combinations of antiretroviral therapies and cope with the side effects of these therapies 
(nausea, vomiting, pain, reduced appetite, weight loss, headaches, diarrhea, constipation, 
anxiety and depression) (Woolridge et al., 2005). Recently, therapeutic use of marijuana has 
emerged as an important issue for people living with HIV/AIDS. Fogarty et al. reported that 
people with HIV/AIDS who use marijuana indicate improved moods, sensory experiences, 
creativity, increased socialising, elation and changes in appetite (Fogarty et al., 2007; 
Woolridge et al., 2005). In 2005 Woolridge et al. surveyed 143 HIV positive people who 
reported using marijuana to manage side effects of long-term anti-retroviral treatment. 
Results were shown in the table below (Table 2.) (Woolridge et al., 2005). 
The ability of cannabinoid to treat pain, nausea, appetite loss, muscle spasm and a wide 
variety of other symptoms causes that more and more HIV/AIDS patients reach for 
marijuana as an alternative remedy. The actual numbers of HIV/AIDS patients that use 
marijuana to treat HIV related symptoms is a difficult number to quantify, but some 
researchers report that this number is quite significant (Cannon, 2010).  
In 1998/1999, in Canada approximately 15% of 977 responders were using marijuana for 
medical purposes (Braitstein et al., 2001). In California in 2001 – 33.3% of the 442 responders 
reported the use of marijuana (Cannon, 2010). Regarding this data, in 2007 scientists 
examined people living with HIV/AIDS in Australia. The results show that among 408 
participants, 59.8% reported some use of marijuana in the past six months. 244 (55.7% of 
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those) reported recreational use only of marijuana and 44.3% admitted mixed use of 
marijuana for therapeutic and recreational purposes (Fogarty et al., 2007). In 2007/2008 in 
South Africa only 3.7% of 618 admitted that was using marijuana in the past six month, 
mostly for stress relief (85.7%) and to a lesser extent for recreational purposes (relaxation) 
(23.5%) and pain relief (17.6%) (Peltzer et al., 2008). These results from different places in the 
world show that substantial proportion of people living with HIV/AIDS use marijuana for 
therapeutic purposes, despite considerable legal barriers, suggesting that cannabis 
represents another option in their health management (Fogarty et al., 2007). The small 
percentage of South Africans with HIV/AIDS using marijuana for therapeutic purposes 
may be caused by poverty (marijuana is more expensive than other alternative, 
supplementary methods like micronutrients, religious healing) and limited access to 




















Lack of appetite 111 79 18 2 0 1 
Pain in muscle 65 63 31 6 0 0 
Nausea 62 56 37 3 2 2 
Anxiety 98 64 49 3 2 2 
Nerve pain 53 51 40 9 0 0 
Depression 94 56 30 9 4 1 
Tingling 46 37 48 9 7 0 
Numbness 42 36 36 24 5 0 
Weight loss 62 45 24 31 0 0 
Headaches 46 35 30 33 2 0 
Tremor 24 37 29 21 13 0 
Constipation 24 21 29 46 4 0 
Tiredness 60 17 33 33 15 2 
Diarrhea 48 13 23 56 6 2 
Vision dimness 22 9 27 55 9 0 
Weakness 48 10 21 54 15 0 
Memory loss 38 13 5 34 34 13 
Slurred speech 9 11 0 78 11 0 
Table 2. Effect of marijuana on Complaint of Symptoms in 143 HIV Patients (from 
Woolridge et al., 2005). 
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4.1 Pain management 
Neuropathic pain and muscular pain is reported by people living with HIV/AIDS. Patients 
describe pain as “aching”, “burning” and “painful numbness” of legs and hands mostly 
(Cannon, 2010). Despite management with opioids and other pain modifying therapies, 
neuropathic pain continues to reduce the quality of life among 30% or more of HIV-infected 
individuals. Scientists suppose that pain perception is modulated by cannabinoid receptors 
in the central and peripheral nervous system (Ellis et al., 2009) via endocannabinoids, an 
endogenous system of retrograde neuromodulatory messengers that work in tandem with 
endogenous opioids (McCarberg, 2007).  
Cannabinoids have been shown to inhibit the experience of pain in both – animal and 
human studies. It was demonstrated in 2007 in a study conducted by Abrams et al. He 
decided to determine the effect of smoked cannabis on the neuropathic pain of HIV-
associated sensory neuropathy and an experimental pain model. Scientists asked fifty 
patients to smoke either cannabis or identical placebo cigarettes with the cannabinoids 
extracted three times daily for 5 days. Reduction in pain intensity was measured. It occurred 
that smoked cannabis reduced daily pain by 34% with placebo. Greater than 30% reduction 
of pain was reported by 52% in the cannabis group and by 24% in the placebo group. The 
first cannabis cigarette reduced chronic pain by a median of 72% vs 15% with placebo 
(Abrams et al., 2007). Similar trial was conducted by American scientists in 2009. Ellis et al. 
examined 127 HIV-associated distal sensory predominant polyneuropathy and measured 
change in pain intensity by the Descriptor Differential Scale (DDS) from a pretreatment 
baseline to the end of each treatment week. Treatments were placebo and delta-9-
tetrahydrocannabinol, smoked four times daily for 5 consecutive days during each of 2 
treatment weeks, separated by a 2-week washout. Among all the patients, pain relief was 
greater with cannabis than placebo and the proportions of subjects achieving at least 30% 
pain relief with cannabis vs placebo were 0.46 and 0.18. Results were shown in Fig. 4. (Ellis 
et al., 2009). This study’s findings are equivalent to those achieved by Abrams et al. in 2007 
and consistent with other recent research supporting the short-term efficacy of cannabis for 
neuropathic pain (Ellis et al., 2009; Abrams et al., 2007).  
Results of other studies show that cannabis can treat not only the neuropathic pain but also 
muscular and chronic pain. Woolridge study demonstrated that 94% of participants 
reported positive results for muscular pain management using marijuana (Cannon, 2010; 
Woolridge et al., 2005). Finally, as it was mentioned in the previous paragraph, 30% 
reduction in chronic pain was reported by 52% of the smoked cannabis group (Cannon, 
2010; Abrams et al., 2007).  
Scientists suppose that analgetic properties of cannabinoids are effect of additional receptor 
and non-receptor mechanisms of their activity. Synergy between opioids and cannabinoids 
may produce opioid-sparing effects, as well as extend the duration of analgesia and reduce 
opioid tolerance and dependence, what is very important in long-term palliative treatment 
(McCarberg, 2007; Karst&Wippermann, 2009). 
4.2 Management of wasting syndrome 
Wasting is big problem for people living with HIV/AIDS and is linked to disease progression 
and death. It is defined as the involuntary loss of more than 10% of normal body weight in 
addition to at least 30 days of diarrhea, fever and generalized weakness. It is caused by 
several factors: 
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Fig. 4. DDS pain severity scores for participants in the cannabis (CNB) and placebo (PCB) 
arms before study treatment (W/I), during each of the 2 treatment weeks (1, 2) and during 
the Washout (W/O) between treatment weeks (from Ellis et al., 2009). 
 Low food intake – low appetite is common among HIV/AIDS patients and is mostly 
caused by anti-retroviral drugs (their side effects such as nausea, changes in the sense of 
taste, or tingling around the mouth also decrease appetite). Moreover, opportunistic 
infections in the mouth, throat or stomach may also reduce food intake. 
 Poor nutrient absorption – opportunistic infections of the gastrointestinal tract can 
interfere with the absorption of nutrients. Moreover, HIV may directly affect the 
intestinal lining and reduce nutrient absorption; diarrhea may affect nutrient absorption 
indirectly – it flushes the system of needed nutrients and calories. 
 Altered metabolism – HIV/AIDS affects food processing and protein building. It is 
probably caused by the increased activity of the immune system. People need more 
calories just to maintain their body weight (Cannon, 2010; The Body, 2011). 
5. Antiemetic action 
Scientists suppose that emesis (the side effect of anti-retroviral therapy) is caused by the 
stimulation of receptors in the central nervous system or the gastrointestinal tract. This 
stimulation appears to be caused by the drug used in treatment itself or a metabolite of the 
drug. The high concentration of cannabinoid receptors in the nucleus of the solitary tract, 
suggest that exogenous cannabinoids bind to receptors and prevent them from binding with 
drugs and metabolites (Szulakowska&Milnerowicz, 2007). Recent findings suggest that the 
mechanism of anti-emetic action of cannabinoids is more complex – CB1 agonist suppresses 
vomiting, which is reversed by CB1 antagonism, and CB1 inverse agonism promotes 
vomiting. Parker et al. proved that cannabinoid agonists –THC suppress nausea. It occurred 
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that cannabidiol (CBD) can also be used in the supplementary therapy of HIV/AIDS. The 
antiemetic effects of CBD may be mediated by indirect activation of somatodendritic 5-HT 
(1A) receptors in the dorsal raphe nucleus; activation of these autoreceptors reduces the 
release of 5-HT in terminal forebrain regions and inhibit nausea and emesis (Parker et al., 
2010). 
In 2001 Tramer et al. decided to search systematically for randomised controlled 
comparisons of the antiemetic efficacy of cannabinoids with any antiemetic or placebo 
(control) in chemotherapy, radiotherapy, surgery or HIV/AIDS.  Scientist analyzed data 
from 30 randomised controlled trials published between 1975 and 1997 (1366 patients). 
Across all the trials, cannabinoids were more effective than active comparators and placebo. 









Control of nausea and vomiting 
Complete control of nausea vs placebo 70 (81/116) 57 (66/115) 
Complete control of vomiting vs placebo 66 (76/116) 36 (41/115) 
Complete control of nausea vs active 
comparator 
59 (122/207) 43 (93/215) 
Complete control of vomiting vs active 
comparator 
57 (111/194) 45 (90/201) 
Patients’ rating 
Cannabinoids vs placebo 76 (153/202) 13 (27/202) 
Cannabinoids vs active comparator 61 (371/604) 26 (156/608) 
Table 3. Control of nausea and vomiting and patients’ preference for treatment in trials of 
cannabinoids against active antiemetic or control treatment (Tramer et al., 2001). 
6. Appetite stimulation 
Cannabinoids can also stimulate appetite and food intake. This property is connected with 
the presence of functional cannabinoid type 1 receptors in the digestive system, especially 
the liver. Hepatocytes express CB1 receptors, the activation of which increase the 
expression of lipogenic genes and de novo fatty acid synthesis, which contributes to the 
development of diet-induced obesity. Cannabinoids can also stimulate AMP-activated 
protein kinase in the hypothalamus, whereas they inhibit it in the liver and adipose 
tissues (Osei-Hyiaman, 2007). Moreover, scientists proved that CBs can activate fatty acid 
synthase (FAS), whereas the inhibition of FAS is a result of profound anorexia. These 
finding thus suggest that the same molecular pathway is involved in both central 
appetitive and the peripheral anabolic effects of cannabinoids 
(Szulakowska&Milnerowicz, 2007; Osei-Hyiaman et al., 2005). 
In 2007 Haney et al. decided to check tolerability and efficacy of smoked marijuana and 
oral dronabinol in HIV-positive marijuana smokers. This placebo-controlled within-
subjects study evaluated marijuana and dronabinol across a range of eating topography 
and mood. Scientists administered 4 times daily for 4 days each dronabinol and 
marijuana, but only one drug was active per day. Administration of drugs was separated 
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by four days of placebo washout. Results were shown in the Fig. 5. In comparison to 
placebo, marijuana and dronabinol increased daily caloric intake and body weight. It is 
probably caused by the increased number of eating occasions – marijuana and dronabinol 
increased the number of eating occasions but didn’t alter the number of calories intake. 
Moreover, marijuana and dronabinol produced significant shifts in the distribution of 
macronutrient administration by enhancing the proportion of calories derived from fat. 
The final effect of increased caloric intake and macronutrients administration was weight 
gain – 1.2 kg after 4 days of dronabinol and 1.1 kg after 4 days of marijuana (Haney et al., 
2007).  
6.1 Mood control 
Scientists consider that prevalence of psychiatric disorders (mostly depression) is really high 
among the people living with HIV/AIDS. In 2001 in the USA nearly half of the population 
screened positive for a psychiatric disorder (36% major depression, 26.5% dysthymia, 15.8% 
generalized anxiety disorder, 10.5% panic attack)(Bing et al., 2001). Psychiatric disorders 
may be triggered by side effects of medications or the effects of HIV on the brain. Research 
show that depression can limit the energy needed to keep focused on staying health and 
may accelerate HIV’s progression to AIDS (The Body, 2002).  
Clinical data suggests that cannabinoids can strongly modulate mood of the people living 
with HIV/AIDS. Marijuana and dronabinol can help to overcome psychiatric disorders like 
anxiety, depression and sleeping disorders. In 2004 Prentiss et al. reported that 60.3% of 133 
people living with HIV/AIDS and coping with psychological disorders recently used 
marijuana to alleviate the symptoms. Only few of them (9.1%) reported smoking 
marijuana/using dronabinol ineffective (Prentiss et al., 2004). Moreover, Haney et al. 
showed also that cannabinoids from marijuana or dronabinol can improve mood without 
producing disruptions in psychomotor functioning and add benefit of improving rating of 
sleep (Haney et al., 2007). In general, people living with HIV/AIDS reported that using 
marijuana cause reduction in stress, relief from anxiety and improve sleep (Cannon, 2010; 
Fogarty et al., 2007). 
Scientists suppose that anti-depressive properties of THC and CBD are probably effect of 
involvement of these cannabinoids in the modulation of serotonergic signaling by their 
capacity to increase the availability of circulating tryptophan (precursor necessary for the 
biosynthesis of the 5-HT). The compensation of tryptophan degradation might be an 
important mechanism, by which THC and CBD may improve mood disturbances – mainly 
cause by alteration of serotonergic activity) (Jenny et al., 2010).   
7. Medical marijuana use – Legal issues 
Scientists from all over the world have explored the use of medical marijuana. Many of them 
have clearly reported that cannabinoids have therapeutic benefits (Cannon, 2010). 
According to this information, many countries, including Canada, Australia, The 
Netherlands and Switzerland, have legalized marijuana for medical purposes. The process 
of legislation of medical marijuana began in the United States in 2005. Today medical 
marijuana is legal at least in thirteen states (Active State Medical Marijuana Programs, 2011). 
Table 4. shows a summary of the main features of medical marijuana programs in different 
countries (Cannon, 2010). 
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Fig. 5. Mean total daily caloric intake and total number of eating occasions as a function of 
marijuana (MJ) and dronabinol (Dronab) dose (Haney et al., 2007). 
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Legal for medical 










Patients must receive a 
prescription from a 
physician 
Canada 









Part of a palliative 
care treatment 
program 
Patients must become 
licensed by the 
Medical Marijuana 
Resource Centre to 
access marijuana 
The Netherlands 
Illegal – exception 











Department of Public 
Health to join the 
program and be 
issued with an 
identification car 
Table 4. A summary of the main features of the medical marijuana programs in different 
countries (Cannon, 2010). 
8. Conclusion 
There is constant debate whether cannabis should be considered therapeutic for HIV/AIDS 
patients. According to the literature, management of HIV-associated symptoms is one of the 
most common applications ascribed to medical marijuana (Prentiss et al., 2004). More and 
more studies have characterized the extent of cannabis use for medical benefit to address HIV-
related symptoms like nausea (Parker et al., 2010), lack of appetite (Tramer et al., 2001), emesis 
(Parker et al., 2010), pain (McCarberg, 2007), depression (Bing et al., 2001), anxiety Haney et al., 
2007) and weight loss (Fogarty et al., 2007). However, it has to be mentioned, that use of 
cannabinoids can have side effects. Several scientists have warned about the negative effects of 
marijuana use on the cardiovascular, respiratory and nervous system (Cannon, 2010; Corless et 
al., 2009), and psychological dysfunction including loss of memory (Seamon et al., 2007) and 
pointed out the necessity for further investigation of the effects of cannabinoids.  Moreover, 
recent legislative efforts to support legalization of medical marijuana suggest the need for 
more precise understanding of the typical patterns and determinants of marijuana use, and 
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better characterization of the epidemiology of cannabis use for relief of symptoms commonly 
associated with HIV/AIDS (Cannon, 2010; Abrams et al., 2007).  
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